Prostate cancer: Potential targets of anti-proliferative and apoptotic signaling pathways

Aarti R. Uzgare, John T. Isaacs

Research output: Contribution to journalShort surveypeer-review

Abstract

Prostate cancers are genetically and phenotypically heterogenous. The heterogeneous nature of prostate cancer may be a consequence of mutations in different cell types (basal stem, transit amplifying or luminal cells) resulting in different malignant maturation pathways. One consistent characterization of these cancers, however, is their eventual progression to a hormonal refractory state. The development of effective novel therapeutic strategies requires an understanding of the mechanisms for the development of such a refractory state. Targeting proliferative and survival pathways provides a rationale for drug design and development for hormone refractory prostate cancer. Prostate cancer cells, however, develop an enhanced redundancy in downstream survival signaling. Hence, new combinational therapies must be developed with the understanding that compensatory mechanisms evolve under selective pressure.

Original languageEnglish (US)
Pages (from-to)707-714
Number of pages8
JournalInternational Journal of Biochemistry and Cell Biology
Volume37
Issue number4
DOIs
StatePublished - Apr 2005

Keywords

  • Cancer stem cell
  • Novel therapies
  • Prostate carcinogenesis
  • Survival pathways

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology

Fingerprint

Dive into the research topics of 'Prostate cancer: Potential targets of anti-proliferative and apoptotic signaling pathways'. Together they form a unique fingerprint.

Cite this